Lumos Diagnostics Holdings (7YU) Stock Overview

Develops, manufactures, and commercializes point-of-care diagnostic products for diagnosis and management of infectious diseases in the United States. More details

7YU fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	2/6
Past Performance	0/6
Financial Health	3/6
Dividends	0/6

Rewards

Revenue is forecast to grow 33.51% per year

Earnings have grown 13.2% per year over the past 5 years

Risk Analysis

Shares are highly illiquid

Has less than 1 year of cash runway

Currently unprofitable and not forecast to become profitable over the next 3 years

7YU Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View Stock Community

Lumos Diagnostics Holdings Limited Competitors

Price History & Performance

Summary of share price highs, lows and changes for Lumos Diagnostics Holdings
Historical stock prices
Current Share Price	AU$0.12
52 Week High	AU$0.12
52 Week Low	AU$0.11
Beta	0.64
1 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	10.62%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	7YU	DE Medical Equipment	DE Market
7D	n/a	-0.8%	0.3%
1Y	n/a	-17.4%	9.1%

Return vs Industry: Insufficient data to determine how 7YU performed against the German Medical Equipment industry.

Return vs Market: Insufficient data to determine how 7YU performed against the German Market.

Price Volatility

Is 7YU's price volatile compared to industry and market?
7YU volatility
7YU Average Weekly Movement	n/a
Medical Equipment Industry Average Movement	5.0%
Market Average Movement	4.9%
10% most volatile stocks in DE Market	12.0%
10% least volatile stocks in DE Market	2.5%

Stable Share Price: 7YU's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: Insufficient data to determine 7YU's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2018	n/a	Doug Ward	lumosdiagnostics.com

Lumos Diagnostics Holdings Limited develops, manufactures, and commercializes point-of-care diagnostic products for diagnosis and management of infectious diseases in the United States. The company’s products include FebriDx, a point-of-care diagnostic test for detecting and differentiating viral and bacterial respiratory infections; and ViraDx, a three-in-one point-of-care test for influenza A, influenza B, and COVID-19. It also provides assay development and manufacturing services for point-of-care tests and proprietary digital reader platforms.

Lumos Diagnostics Holdings Limited Fundamentals Summary

How do Lumos Diagnostics Holdings's earnings and revenue compare to its market cap?
7YU fundamental statistics
Market cap	€104.67m
Earnings (TTM)	-€6.16m
Revenue (TTM)	€10.63m

9.8x

P/S Ratio

-17.0x

P/E Ratio

Is 7YU overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
7YU income statement (TTM)
Revenue	US$12.40m
Cost of Revenue	US$4.72m
Gross Profit	US$7.68m
Other Expenses	US$14.86m
Earnings	-US$7.18m

Last Reported Earnings

Jun 30, 2025

Next Earnings Date

n/a

Earnings per share (EPS)	-0.0091
Gross Margin	61.93%
Net Profit Margin	-57.93%
Debt/Equity Ratio	0%

How did 7YU perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/12/03 11:20
End of Day Share Price	2025/12/03 00:00
Earnings	2025/06/30
Annual Earnings	2025/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Lumos Diagnostics Holdings Limited is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Chris Kallos	MST Financial Services Pty Limited